Shows
Evidence-Based GI: An ACG Publication and PodcastHow Effective Are Obesity Medications for Reducing Hepatic Decompensation in NASH?Philip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD discuss “Association of Glucagon-Like Peptide-1 Receptor Agonists with Serious Liver Events among Patients with Type 2 Diabetes Mellitus: A Scandinavian Cohort Study,” Engstom A, Wintzell V, Melbye M, et al. Hepatology 2024; In Press.2024-04-2413 minEvidence-Based GI: An ACG Publication and PodcastContinued Treatment With Tirzepatide Is Necessary to Maintain Weight LossPhilip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD discuss “Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial,” by Aronne LJ, Horn DB, Bays HE, et al. JAMA 2024; 3310: 38-48.2024-02-2113 minEvidence-Based GI: An ACG Publication and PodcastGI Adverse Events with GLP-1 Agonists for Weight Loss: Understanding the RisksPhilip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD, MS discuss “Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss,” by Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. JAMA Medicine 2023; In Press.2023-11-1511 minEvidence-Based GI: An ACG Publication and PodcastHepatitis C Virus Testing and Treatment - A Call To ActionPhilip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD, MS discuss “Hepatitis C Treatment Initiation Among US Medicaid Enrollees,” by Kapadia SN, Zhang H, Gonzalez CJ, et al. JAMA Netw Open. 2023 Aug 1;6(8):e2327326.2023-10-1812 min